Nishita Narwal | Microbiology | Women Researcher Award

Women Researcher Award

Nishita Narwal
The University of Western Australia, Australia

Nishita Narwal
Affiliation The University of Western Australia
Country Australia
Google Scholar ID ZM087PsAAAAJ
Documents 23
Citations 588
h-index 10
Subject Area Microbiology
Event International Molecular Biologist Awards
ORCID 0000-0001-5043-8949
Scopus 58289605900

Nishita Narwal is a researcher affiliated with The University of Western Australia, Australia, whose stated subject area is Microbiology. Her academic profile is associated with scholarly research and publication activity in this broad biological science discipline. Microbiology examines microorganisms and their interactions with living systems, environments, and biological processes.[1] [2]

Abstract

This academic profile presents Nishita Narwal, a researcher affiliated with The University of Western Australia, Australia, with Microbiology identified as her subject area. The supplied scholarly profile reports 23 documents, 588 citations, and an h-index of 10. These bibliometric indicators provide a quantitative overview of publication activity and citation influence, although they do not independently measure the originality, methodological quality, or practical significance of individual research contributions. [1] [2]

Keywords

Nishita Narwal; Women Researcher Award; Microbiology; molecular biology; microbial research; scholarly publications; research assessment; citation analysis; academic impact; scientific contributions; women in science; Australia.

Introduction

Microbiology is a scientific discipline concerned with the study of microorganisms, including bacteria, viruses, fungi, archaea, and microscopic eukaryotes. It investigates their structure, physiology, genetics, ecological roles, and interactions with other organisms. Research in this field contributes to understanding biological processes and supports developments in healthcare, biotechnology, agriculture, environmental science, and molecular biology. [4]

Academic assessment in microbiology requires consideration of the originality of research questions, the reliability of experimental methods, the quality of published evidence, and the relevance of findings to the scientific community. Citation metrics can complement qualitative evaluation, but their interpretation should account for differences in publication practices, disciplinary citation patterns, and database coverage. [3]

Research Profile

Nishita Narwal is affiliated with The University of Western Australia, Australia. Microbiology is the subject area identified in the supplied academic information. Her scholarly profile can be explored through the available Google Scholar, Scopus, and ORCID records, which provide complementary information about researcher identity, publications, and academic activity. [1] [2] [5]

The supplied Google Scholar identifier is ZM087PsAAAAJ. The Scopus author identifier is 58289605900, and the ORCID iD is 0000-0001-5043-8949. These identifiers provide access points for examining scholarly records and distinguishing researcher profiles. However, bibliographic databases may contain incomplete entries, duplicate records, or author attribution differences, making publication-level verification important for formal academic evaluation.

Research Contributions

Research contributions in microbiology can advance scientific understanding through the identification of microbial mechanisms, investigation of biological interactions, characterization of microorganisms, and development of experimental or analytical approaches. The significance of a contribution depends on the research question, methodological reliability, reproducibility, and the extent to which the findings contribute to existing scientific knowledge.

An evidence-based assessment of Nishita Narwal’s research contributions may consider the following academic dimensions:

  • Originality and scientific relevance of the research questions addressed.
  • Application of appropriate microbiological and molecular research methodologies.

Publications

The supplied academic profile reports 23 documents associated with Nishita Narwal. This figure provides an overview of the reported publication record, but the precise total may vary across scholarly databases because of differences in indexing coverage, document classification, author-name matching, and profile updates. [1] [2]

A comprehensive publication review should examine the researcher’s journal articles, review papers, conference contributions, and other scholarly outputs where applicable. Relevant bibliographic details include article titles, author lists, journal names, publication dates, volume and issue information, page numbers, and Digital Object Identifiers. These details help establish the accuracy and traceability of the academic record.

Research Impact

The supplied bibliometric information for Nishita Narwal includes 588 citations and an h-index of 10, alongside 23 reported documents. These indicators offer quantitative information about publication output and citation activity. Since citation counts and author metrics are updated periodically and may differ across databases, the figures should be interpreted as a snapshot of the supplied profile rather than permanent values. [1] [2]

The h-index is a bibliometric indicator that combines the number of publications with their citation counts. An h-index of 10 indicates that ten publications have each received at least ten citations within the database and measurement context used. The indicator provides one perspective on scholarly influence but does not directly measure originality, research integrity, methodological quality, or the practical significance of scientific findings. [3]

Award Suitability

The Women Researcher Award recognizes the importance of women’s contributions to scientific research and academic development. Within the International Molecular Biologist Awards, this category provides a context for acknowledging documented research contributions, scholarly achievements, and engagement with scientific advancement. The evaluation of any candidate should be based on the official award criteria and verifiable evidence rather than demographic or bibliometric information alone.

The academic profile of Nishita Narwal includes an affiliation with The University of Western Australia and a stated subject area of Microbiology. The supplied publication and citation indicators provide additional bibliometric context. A comprehensive evaluation of her suitability for research recognition may consider the following dimensions:

Conclusion

Nishita Narwal is identified in the supplied academic information as a researcher affiliated with The University of Western Australia, Australia, with Microbiology listed as her subject area. Her reported scholarly profile includes 23 documents, 588 citations, and an h-index of 10. Her ORCID, Scopus, and Google Scholar identifiers provide accessible resources for examining her academic records and associated publications.

The profile offers a structured overview of the researcher’s academic information and bibliometric indicators in the context of the Women Researcher Award under the International Molecular Biologist Awards.

References

  1. Elsevier. (n.d.). Scopus author details: Nishita Narwal, Author ID 58289605900.
    https://www.scopus.com/authid/detail.uri?authorId=58289605900
  2. Google Scholar. (n.d.). Nishita Narwal: Google Scholar author profile.
    https://scholar.google.com/citations?hl=en&user=ZM087PsAAAAJ
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  4. Microbiology Society. (n.d.). Microbiology and the study of microorganisms.
    https://microbiologysociety.org/
  5. ORCID. (n.d.). Nishita Narwal researcher identifier: 0000-0001-5043-8949. ORCID. Public researcher identifier and associated profile information.
    https://orcid.org/0000-0001-5043-8949

Camille EVRARD | Molecular Biology | Best Researcher Award

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.
  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.
  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.
  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.
  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.